Discover
CMPS
COMPASS Pathways plc
15.19
2 x 11.01
2 x 19.08
bid
ask
+
0.19
1.27%
2 @ 07:55 PM
15.20 +0.01 (0.06%)
| Ytd | 120.14% | |
| 1y | 199.02% |
14.76
day range
15.43
4.90
52 week range
15.19
| Open | 15.15 | Prev Close | 15.00 | Low | 14.76 | High | 15.43 | Mkt Cap | 2.10B |
| Vol | 3.57M | Avg Vol | 3.45M | EPS | -3.79 | P/E | N/A | Forward P/E | -10.60 |
| Beta | 2.55 | Short Ratio | 5.45 | Inst. Own | 68.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 13.20 | 200-d Avg | 9.53 | 1yr Est | 23.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.36 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.46 | -0.36 | 0.1 | 21.74% |
| 2026-05-13 | 2026-03 | -0.45 | -0.3 | 0.15 | 33.33% |
| 2026-03-24 | 2025-12 | -0.41 | -1 | -0.59 | -143.90% |
| 2025-11-04 | 2025-09 | -0.4 | -1.44 | -1.04 | -260.00% |
| 2025-07-31 | 2025-06 | -0.37 | -0.38 | -0.01 | -2.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-06 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-08-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-08-06 | B. Riley Securities | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Equal-Weight | |
| 2026-07-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-25 | ATAI LIFE SCIENCES NV | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-10-23 | GOLDSMITH GEORGE JAY | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-03-25 | LOXAM TERI | Chief Financial Officer | 152.00K | Stock Award(Grant) |
| 2024-10-23 | MALIEVSKAIA EKATERINA | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-03-25 | NATH KABIR | Chief Executive Officer | 366.99K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Deep Track Capital, Lp | 12.16M | 184.73M | 8.78% |
| 2026-06-29 | RTW Investments LP | 10.70M | 162.55M | 7.73% |
| 2026-06-29 | BIT Capital GmbH | 6.35M | 96.44M | 4.58% |
| 2026-06-29 | Tang Capital Management, LLC | 5.00M | 75.95M | 3.61% |
| 2026-06-29 | Two Sigma Investments, LP | 4.47M | 67.91M | 3.23% |
| 2026-06-29 | Marshall Wace LLP | 4.33M | 65.75M | 3.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | ARK ETF Trust-ARK Genomic Revolution ETF | 4.72M | 71.67M | 3.41% |
| 2026-07-30 | iShares Trust-iShares Biotechnology ETF | 795.55K | 12.08M | 0.57% |
| 2026-08-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 454.54K | 6.90M | 0.33% |
| 2026-04-29 | Columbia Funds Series Trust I-Columbia Small Cap Value Discovery Fund | 420.91K | 6.39M | 0.30% |
| 2026-06-29 | ROYCE FUND-Royce Smaller-Companies Growth Fund | 178.00K | 2.70M | 0.13% |
| 2026-06-29 | Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 114.28K | 1.74M | 0.08% |